Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection.
Ribocure supports RARE DISEASE DAY on February 29th
Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter
Ribocure Clinic marks milestone with their first patients enrolled
Ribo announce the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023
Ribo visar upp lovande forskningsresultat för tre RNA-baserade läkemedel vid European Society of Cardiology Congress 2023
Ribocure Pharmaceuticals was officially inaugurated on June 30th 2023
Ribocure Pharmaceuticals invigde sina nya lokaler i GoCo Clinic huset den 30 juni 2023
